{"id":7631,"date":"2023-08-19T09:31:36","date_gmt":"2023-08-19T09:31:36","guid":{"rendered":"http:\/\/d1s07skqdwll4z.cloudfront.net\/mrcc-tool\/reference-list\/"},"modified":"2024-12-19T08:49:32","modified_gmt":"2024-12-19T08:49:32","slug":"reference-list","status":"publish","type":"page","link":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/mrcc-tool\/reference-list\/","title":{"rendered":"Reference list"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:-60px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-search-element fusion-search-element-1 fusion-search-form-clean\" style=\"--awb-border-radius:7px;--awb-text-color:var(--awb-color8);--awb-border-color:var(--awb-color8);--awb-bg-color:var(--awb-color3);\">\t\t<form role=\"search\" class=\"searchform fusion-search-form  fusion-live-search fusion-search-form-clean\" method=\"get\" action=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/\">\n\t\t\t<div class=\"fusion-search-form-content\">\n\n\t\t\t\t\n\t\t\t\t<div class=\"fusion-search-field search-field\">\n\t\t\t\t\t<label><span class=\"screen-reader-text\">Search for:<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<input type=\"search\" class=\"s fusion-live-search-input\" name=\"s\" id=\"fusion-live-search-input-0\" autocomplete=\"off\" placeholder=\"Search...\" required aria-required=\"true\" aria-label=\"Search...\"\/>\n\t\t\t\t\t\t\t\t\t\t\t<\/label>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"fusion-search-button search-button\">\n\t\t\t\t\t<input type=\"submit\" class=\"fusion-search-submit searchsubmit\" aria-label=\"Search\" value=\"&#xf002;\" \/>\n\t\t\t\t\t\t\t\t\t\t<div class=\"fusion-slider-loading\"><\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t<input type=\"hidden\" name=\"post_type[]\" value=\"any\" \/><input type=\"hidden\" name=\"search_limit_to_post_titles\" value=\"0\" \/><input type=\"hidden\" name=\"live_min_character\" value=\"4\" \/><input type=\"hidden\" name=\"live_posts_per_page\" value=\"100\" \/><input type=\"hidden\" name=\"live_search_display_featured_image\" value=\"1\" \/><input type=\"hidden\" name=\"live_search_display_post_type\" value=\"1\" \/><input type=\"hidden\" name=\"fs\" value=\"1\" \/>\n\t\t\t<\/div>\n\n\n\t\t\t\t\t\t\t<div class=\"fusion-search-results-wrapper\"><div class=\"fusion-search-results\"><\/div><\/div>\n\t\t\t\n\t\t<\/form>\n\t\t<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Referenceliste<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-2 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Introduktion<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-3 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 1.1<\/h4><\/div><div class=\"fusion-text fusion-text-1\"><div>\n<ol>\n<li><i>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: 10.3322\/caac.21660. Epub 2021 Feb 4. PMID: 33538338.<\/i><\/li>\n<li><i>Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022;82(5):529-542. doi: 10.1016\/j.eururo.2022.08.019. Epub 2022 Sep 10. PMID: 36100483.<\/i><\/li>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa. Renalcellecarcinomer-onkologisk behandling. Version 3.0 Kliniske Retningslinjer.<\/i><\/li>\n<li><i>RADS. Baggrundsnotat for medicinsk behandling af metastaserende nyrekr\u00e6ft. 2016.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-4 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 1.2<\/h4><\/div><div class=\"fusion-text fusion-text-2\"><div>\n<ol>\n<li><i>Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;1-15.<\/i><\/li>\n<li><i>Linehan WM, Rini BI, Yang JC. Cancer of the kidney. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg\u2019s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2011. p. 1161-1182.<\/i><\/li>\n<li><i>Zhou M, Hattab EM, Eble JN, Cheng L. Neoplasms of the kidney. In: Zhou M, Galluzzi-Magi C, editors. Genitourinary Pathology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2015. p. 306-377.<\/i><\/li>\n<li><i>https:\/\/www.europeanurology.com\/article\/S0302-2838(18)30633-X\/fulltext<\/i><\/li>\n<li><i>Bukavina L, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update European UrologyVol. 82Issue 5p529\u2013542Published online: September 10, 2022<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-5 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 1.3<\/h4><\/div><div class=\"fusion-text fusion-text-3\"><div>\n<ol>\n<li><i>WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. In: WHO Classification of Tumours, 5th Edition, Volume 8. 2022. ISBN 978-92-832-4512-4.<\/i><\/li>\n<li><i>Moch, H., et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2022. 82: 458.<\/i><\/li>\n<li><i>WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. In: WHO Classification of Tumours, 5th Edition, Volume 8. 2022. ISBN 978-92-832-4512-4.<\/i><\/li>\n<li><i>Hora, M., et al. European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist\u2019s Point of View. Eur Urol, 2023. 83: 97.<\/i><\/li>\n<li><i>Amin, M.B., et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol, 2014. 38: 871.<\/i><\/li>\n<li><i>Abern, M.R., et al. Characteristics and outcomes of tumors arising from the distal nephron. Urology, 2012. 80: 140.<\/i><\/li>\n<li><i>European Association of Urology. EAU Guidelines on Renal Cell Carcinoma 2024. Available from: https:\/\/uroweb.org\/guidelines\/renal-cell-carcinoma\/chapter\/epidemiology-aetiology-and-pathology<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-6 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 1.4<\/h4><\/div><div class=\"fusion-text fusion-text-4\"><div>\n<ol>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa. Renalcellecarcinomer &#8211; Kirurgisk behandling. Version 3.1. Kliniske Retningslinjer. Faglig godkendelse 12. januar 2024. Administrativ godkendelse 12. marts 2024.<\/i><\/li>\n<li><i>Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanesvaran R, Reaume MN, Canil C, Choueiri TK, Heng DYC. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Netw Open. 2021 Jan 4;4(1):e2021869. doi: 10.1001\/jamanetworkopen.2020.21869. PMID: 33475752; PMCID: PMC7821027.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-7 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 1.5<\/h4><\/div><div class=\"fusion-text fusion-text-5\"><div>\n<ol>\n<li><i>European Association of Urology. EAU Guidelines on Renal Cell Carcinoma 2024. Available from: https:\/\/uroweb.org\/guidelines\/renal-cell-carcinoma\/chapter\/staging-and-classification-systems<\/i><\/li>\n<li><i>Van de Pol, J.A.A., et al. Etiologic heterogeneity of clear-cell and papillary renal cell carcinoma in the Netherlands Cohort Study. Int J Cancer, 2021. 148: 67.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-8 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 1.6<\/h4><\/div><div class=\"fusion-text fusion-text-6\"><div>\n<ol>\n<li><i>Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119-1132.<\/i><\/li>\n<li><i>Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010;61:329-343.<\/i><\/li>\n<li><i>Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664-3671.<\/i><\/li>\n<li><i>Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2010;10(7):658-664.<\/i><\/li>\n<li><i>Pili R, Kauffman E, Rodriguez R. Cancer of the kidney. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, editors. Abeloff\u2019s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2014. p. 1416-1444.<\/i><\/li>\n<li><i>Choueiri TK, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-23.<\/i><\/li>\n<li><i>Gibney GT, et al. Safety and clinical activity of pembrolizumab in patients with advanced, programmed death ligand 1-positive, non-small-cell lung cancer: a phase 1 trial. Ann Oncol. 2013;24(7):343-9.<\/i><\/li>\n<li><i>Rankin EB, et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Proc Natl Acad Sci USA. 2014;111(37):13373-8.<\/i><\/li>\n<li><i>Zhou L, et al. Oncogenic role and therapeutic target of the hypoxia-inducible factor-2\u03b1 in renal cell carcinoma. Oncogene. 2016;35(21):2687-97.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-9 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Symptomer og diagnose<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-10 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 2.1<\/h4><\/div><div class=\"fusion-text fusion-text-7\"><ol class=\"reference\">\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa. Renalcellecarcinomer &#8211; onkologisk behandling. Version 3.0. Kliniske Retningslinjer. Faglig godkendelse 25. januar 2024. Administrativ godkendelse 12. februar 2024. Available from: https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer\u2014skabeloner-og-vejledninger\/kliniske-retningslinjer-opdelt-pa-dmcg\/darenca\/darenca_onkologi_v3.0_admgod_120224.pdf.<\/i><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-11 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 2.2<\/h4><\/div><div class=\"fusion-text fusion-text-8\"><div>\n<ol>\n<li><i>ESMO Guidelines: European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Available from: https:\/\/www.esmo.org\/guidelines.<\/i><\/li>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa Kliniske Retningslinjer 2024. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/nyrecancer\/<\/i><\/li>\n<li><i>NCCN Guidelines: National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Available from: https:\/\/www.nccn.org\/guidelines.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-12 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 2.3<\/h4><\/div><div class=\"fusion-text fusion-text-9\"><div>\n<ol>\n<li><i>ESMO Guidelines: European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Available from: https:\/\/www.esmo.org\/guidelines.<\/i><\/li>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa Kliniske Retningslinjer 2024. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/nyrecancer\/<\/i><\/li>\n<li><i>NCCN Guidelines: National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Available from: https:\/\/www.nccn.org\/guidelines.<\/i><\/li>\n<li><i>European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. 2024. Available from: https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-13 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 2.4<\/h4><\/div><div class=\"fusion-text fusion-text-10\"><div>\n<ol>\n<li><i>Prognostication in Kidney Cancer: Recent Advances and Future Directions Jeffrey Graham, Shaan Dudani, and Daniel Y.C. Heng<\/i><\/li>\n<li><i>European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Available from: https:\/\/www.esmo.org\/guidelines.<\/i><\/li>\n<li><i>Motzer RJ, Bacik J, Murphy BA, et al:Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002<\/i><\/li>\n<li><i>International mRCC Database Consortium (IMDC). Last accessed: April 2024. Available from: https:\/\/www.imdconline.com.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-14 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 2.5<\/h4><\/div><div class=\"fusion-text fusion-text-11\"><div>\n<ol>\n<li><i>Prognostication in Kidney Cancer: Recent Advances and Future Directions Jeffrey Graham, Shaan Dudani, and Daniel Y.C. Heng<\/i><\/li>\n<li><i>European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. 2024. Available from: https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma.<\/i><\/li>\n<li><i>Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin, Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers, European Urology, Volume 73, Issue 4, 2018, Pages 560-569, ISSN 0302-2838,<\/i><\/li>\n<li><i>Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013 Oct;37(10):1490-504. doi: 10.1097\/PAS.0b013e318299f0fb. PMID: 24025520.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-15 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">H\u00e5ndtering af mRCC<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-16 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 3.1<\/h4><\/div><div class=\"fusion-text fusion-text-12\"><div>\n<ol>\n<li><i>ESMO Guidelines: European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Available from: https:\/\/www.esmo.org\/guidelines.<\/i><\/li>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa Kliniske Retningslinjer 2024. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/nyrecancer\/<\/i><\/li>\n<li><i>European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. 2024. Available from: https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma.<\/i><\/li>\n<li><i>Medicinr\u00e5det. Medicinr\u00e5dets protokol for en f\u00e6lles behandlingsvejledning og l\u00e6gemiddelrekommandation vedr\u00f8rende nyrekr\u00e6ft. Sygdomsomr\u00e5de: Kr\u00e6ftsygdomme (Cancer). Specifik sygdom: Nyrekr\u00e6ft (Renalcellekarcinom). Anvendelse: Nyrekr\u00e6ft. Fagudvalg: Nyrekr\u00e6ft. Sidst opdateret: 08. juli 2024. Available from: https:\/\/medicinraadet.dk\/anbefalingerogvejledninger\/behandlingsvejledningeroglaegemiddelrekommandationer\/nyrekraeft#:~:text=Medicinr%C3%A5dets%20protokol%20for%20en%20f%C3%A6lles.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-17 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.2<\/h4><\/div><div class=\"fusion-text fusion-text-13\"><ol>\n<li><em>The Cancer Department, Herlev Hospital<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-18 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.3<\/h4><\/div><div class=\"fusion-text fusion-text-14\"><ol>\n<li><em>The Cancer Department Herlev Hospital<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-19 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 3.4<\/h4><\/div><div class=\"fusion-text fusion-text-15\"><div>\n<ol>\n<li><i>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.<\/i><\/li>\n<li><i>Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-52.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-20 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 3.5<\/h4><\/div><div class=\"fusion-text fusion-text-16\"><div>\n<ol>\n<li><i>Andersen S, Ottesen S, Neergaard MA, Jespersen B, S\u00f8rensen J. Symptomkontrol i palliativ medicin. 6th ed. Copenhagen: FADL\u2019s Forlag; 2019.<\/i><\/li>\n<li><i>SKA (sammenslutningen af danske kr\u00e6ftafdelinger), http:\/\/www.skaccd.org\/<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-21 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 3.6<\/h4><\/div><div class=\"fusion-text fusion-text-17\"><div>\n<ol>\n<li><i>Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982<\/i><\/li>\n<li><i>Karnofsky DA, Burchenal JH. In: Evaluation of chemotherapeutic agents. MacLeod CM, editor. New York: Columbia University Press; 1949. The clinical evaluation of chemotherapeutic agents in cancer; pp. 191\u2013205<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-5 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-22 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Behandling<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-23 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 4.1<\/h4><\/div><div class=\"fusion-text fusion-text-18\"><div>\n<ol>\n<li><i>Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-27.<\/i><\/li>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa Kliniske Retningslinjer 2024. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/nyrecancer\/<\/i><\/li>\n<li><i>Freed SZ, Halperin JP, Gordon M. Radiographic regression of metastases from renal cell carcinoma. J Urol. 1977;118(4):538-42.<\/i><\/li>\n<li><i>Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol. 2018;74(6):805-9.<\/i><\/li>\n<li><i>Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019;111-128.<\/i><\/li>\n<li><i>ESMO Guidelines: European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Available from: https:\/\/www.esmo.org\/guidelines.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-24 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 4.2<\/h4><\/div><div class=\"fusion-text fusion-text-19\"><div>\n<ol>\n<li><i>Delacroix SE, Wood CG, Jonasch E. Renal neoplasia. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, et al, editors. Brenner &amp; Rector\u2019s The Kidney. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012. p. 1508-35.<\/i><\/li>\n<li><i>Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma: 2016 update. European Association of Urology. [Accessed June 25, 2016]. Available from: https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma\/<\/i><\/li>\n<li><i>Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii49-iii56.<\/i><\/li>\n<li><i>Pili R, Kauffman E, Rodriguez R. Cancer of the kidney. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, editors. Abeloff\u2019s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2014. p. 1416-44.e5. Chapter 82.<\/i><\/li>\n<li><i style=\"color: var(--awb-text-color); font-family: var(--awb-text-font-family); font-size: var(--awb-font-size); font-weight: var(--awb-text-font-weight); letter-spacing: var(--awb-letter-spacing); text-align: var(--awb-content-alignment); text-transform: var(--awb-text-transform); background-color: var(--awb-bg-color-hover);\">Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119-1132; DOI: 10.1016\/S0140-6736(09)60229-4<\/i><\/li>\n<li><i>Banumathy G, Cairns P. Renal cell carcinoma: molecular biology and targeted therapy. Cancer Biol Ther. 2010;10(7):658-64.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-25 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 4.3<\/h4><\/div><div class=\"fusion-text fusion-text-20\"><div>\n<ol>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa Kliniske Retningslinjer 2024. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/nyrecancer\/<\/i><\/li>\n<li><i>Fishman M, Choueiri TK, Fay AP, et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMsm registry. J Immunother Cancer. 2019.<\/i><\/li>\n<li><i>Considine B, Hurwitz M. Current status and future directions of immunotherapy in renal cell carcinoma. Curr Oncol Rep. 2019.<\/i><\/li>\n<li><i>Kjeldsen JW, Lorentzen CL, Martinenaite E, et al. Cancer immunotherapy. Ugeskr Laeger. 2018.<\/i><\/li>\n<li><i>Ribas A, Wolchok JD, Hodi FS, et al. Tumour immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517-29.<\/i><\/li>\n<li><i>Kondrup T, Hansen S, Andersen MH, et al. Immunotherapy is cancer treatment with a completely new adverse reaction profile. Ugeskr Laeger. 2017.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-26 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 4.4<\/h4><\/div><div class=\"fusion-text fusion-text-21\"><div>\n<ol>\n<li><i>Danish Cancer Society. Radiation therapy for cancer treatment. Available from: https:\/\/www.cancer.dk\/fakta-kraeft\/behandling-for-kraeft\/behandlingsformer\/straalebehandling\/. Accessed 2024 Sep 4.<\/i><\/li>\n<li><i>Danish Multidisciplinary Cancer Groups (DMCG). DaRenCa Kliniske Retningslinjer 2024. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/nyrecancer\/<\/i><\/li>\n<li><i>ESMO Guidelines: European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Available from: https:\/\/www.esmo.org\/guidelines.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-27 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Referencer 4.5<\/h4><\/div><div class=\"fusion-text fusion-text-22\"><div>\n<ol>\n<li><i>Sinibaldi VJ, Smithfield R, Johnson T, et al. Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care. J Clin Oncol. 2018.<\/i><\/li>\n<li><i>Danish Cancer Society. Behandling for kr\u00e6ft. Available from: https:\/\/www.cancer.dk\/fakta-kraeft\/behandling-for-kraeft\/. Accessed 2024 Sep 4.<\/i><\/li>\n<li><i>Andersen S, et al. Symptomkontrol i palliativ medicin. 5th ed. Copenhagen: FADL\u2019s Forlag; 2012.<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-6 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-28 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">H\u00e5ndtering af toksicitet<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-29 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.1<\/h4><\/div><div class=\"fusion-text fusion-text-23\"><ol>\n<li><i>Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11(2):172-191. doi:10.1016\/j.ejcsup.2013.07.016<\/i><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-30 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.2.2<\/h4><\/div><div class=\"fusion-text fusion-text-24\"><ol>\n<li><em>Dobbin et al, Heart 2018<\/em><\/li>\n<li><i>Dansk Cardiologisk Selskab https:\/\/www.cardio.dk\/<\/i><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-31 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.2.7<\/h4><\/div><div class=\"fusion-text fusion-text-25\"><div>\n<ol>\n<li><i>Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management &#8211; PubMed<\/i><\/li>\n<li><i>Dansk Endokrinologisk Selskab, Available from: https:\/\/endocrinology.dk\/<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><div class=\"fusion-title title fusion-title-32 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.3<\/h4><\/div><div class=\"fusion-text fusion-text-26\"><div>\n<ol>\n<li><i>Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158-168.<\/i><\/li>\n<li><i>Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv141<\/i><\/li>\n<li><i> Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768<\/i><\/li>\n<li><i>Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018;23(3):410-420<\/i><\/li>\n<li><i>Kondrup M, Raunkilde L, Svane IM, Schmidt H, Bastholt L. Immunotherapy is cancer treatment with a completely new adverse reaction profile. Ugeskr Laeger. 2017;179(2):138-142<\/i><\/li>\n<li><i>Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86-104<\/i><\/li>\n<li><i>Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559-574<\/i><\/li>\n<\/ol>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-7 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:7px;--awb-border-radius-top-right:7px;--awb-border-radius-bottom-right:7px;--awb-border-radius-bottom-left:7px;--awb-overflow:hidden;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-33 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-margin-top:25px;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Oversigt over alle kapitler<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_1_6 1_6 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:16.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:11.52%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:11.52%;--awb-width-medium:16.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:11.52%;--awb-spacing-left-medium:11.52%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_2_3 2_3 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-1 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_bevel_color:rgba(89,96,104,0.7);--button_bevel_color_hover:rgba(89,96,104,0.9);--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:15px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/mrcc-tool\/1-introduction-rcc\/\"><span class=\"fusion-button-text\">1. Introduktion til RCC<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-2 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/mrcc-tool\/2-symptoms-and-diagnosis\/\"><span class=\"fusion-button-text\">2. Symptomer og diagnose<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-3 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/mrcc-tool\/3-management-of-mrcc\/\"><span class=\"fusion-button-text\">3. H\u00e5ndtering af mRCC<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-4 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/mrcc-tool\/4-treatment\/\"><span class=\"fusion-button-text\">4. Behandling<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-5 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/mrcc-tool\/5-toxicity-management\/\"><span class=\"fusion-button-text\">5. Toksiciteter<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-6 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/frequently-asked-questions-faqs\/\"><span class=\"fusion-button-text\">6. Ofte stillede sp\u00f8rgsm\u00e5l<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_1_6 1_6 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:16.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:11.52%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:11.52%;--awb-width-medium:16.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:11.52%;--awb-spacing-left-medium:11.52%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":7455,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7631","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/pages\/7631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/comments?post=7631"}],"version-history":[{"count":24,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/pages\/7631\/revisions"}],"predecessor-version":[{"id":12091,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/pages\/7631\/revisions\/12091"}],"up":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/pages\/7455"}],"wp:attachment":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/da\/wp-json\/wp\/v2\/media?parent=7631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}